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prescription dose was escalated to the maximum level 
achievable for each patient according to predefined organs at 
risk (OAR) toxicity and dose constraints. Radiobiological 
models were used to predict a patient-specific radiotherapy 
(RT) dose associated with a 10% risk of grade 3 and above 
pneumonitis which was then constrained to a prescription 
dose of 63-73 Gy in 30# for IDEAL-CRT (plus concurrent 
chemotherapy) and 55-65 Gy in 20# for I-START. These are 
the first multi-centre trials in the UK to investigate isotoxic 
dose escalation and as such incorporated a thorough Quality 
Assurance (QA) programme to ensure protocol compliance. 
Materials and Methods: RT plans were produced across 8 
centres for IDEAL and 12 centres for I-START. Full 3D RT 
planning data was submitted to a central QA contact. All RT 
plans and plan assessment forms were analysed for quality 
and protocol compliance. 
Results: Between 2010 and 2014, 84 and 81 patients were 
recruited to IDEAL-CRT and I-START respectively. Table 1 
shows the average doses received by OAR and targets 




Patients not reaching the suggested CTV and PTV dose 
coverage were not considered protocol deviations as this was 
a recommendation only.  
2/84 IDEAL-CRT patients exceeded 1 or more of the Lungs-
GTV dose limits and 1 patient exceeded the brachial plexus 
dose to 0.1cc. 2/81 I-START patients exceeded the spinal 
cord dose tolerance quoted in V1.0 of the protocol. Brachial 
plexus dose deviations were seen in 3 I-START patients with 2 
patients exceeding the tolerance dose stated in V1.0 and 1 
patient exceeding the dose in V2.0 of the trial protocol. The 
initial cautious dose constraints stated in V1.0 of the I-START 
protocol were modified in V2.0 to reflect standard clinical 
practice and achieve consistency with IDEAL-CRT. No 
protocol deviations were seen in the dose to the heart and 
oesophagus in both trials. 
Conclusions: Protocol deviations for IDEAL-CRT and I-START 
were seen in less than 4% and 6% of patients respectively. 
Complex dose escalation trials can be carried out in a 
multicentre setting provided there is a comprehensive pre-
trial and on-trial QA programme in place.  
IDEAL-CRT (C13530/A17007) and ISTART (C25518/A11535) are 
funded by Cancer Research UK. 
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Purpose/Objective: Concurrent chemo-radiation (CRT) is the 
treatment of choice for local advanced NSCLC patients. 
Despite the curative intent of the treatment, survival is poor 
with a median survival of about 16-18 months (m) and a 5 
year (y) survival of 15%. The loco-regional control rate at 2 y 
is only about 30% in clinical trials. This randomized phase-II 
trial tested a dose intense oral vinorelbine (Nav) regimen 
with two doses of RT, 60 Gy/30 F (arm A) and 66 Gy/33 F 
(arm B). 
Materials and Methods: Before randomization to arm A or B, 
the patients were treated with 2 cycles of induction 
chemotherapy (Carboplatin+Nav). In both arms, Nav was 
given as concurrent chemotherapy (a fixed dose of 50 mg 
3/week for the full course of CRT). Follow-up CT-scans were 
performed every 3 m starting 1 m after commencing 
radiotherapy for 2 y and then every 6 m. As part of the 
protocol, a PET-CT scan was conducted 9 m after 
randomization.  
The primary endpoint was the Local Progression Free Survival 
Rate (LPFSR). The goal of the study was within the 95% 
confidence interval (95%CI) to have a LPFSR at 9 m of 80%. 
Log rank tests were used to test survival. 
Results: In arm A and B, 59 and 58 patients were eligible. 
The two arms were well balanced. The minimum and median 
potential follow-up was 14.5 and 32.6 m, respectively. The 
median number of Nav was 18 x in arm A and 20 x in arm B. 
Of the patients, 10% had ≤12 x Nav. The LPFSR at 9 m was in 
arm A: 54% (95%CI: 43%; 64%), and in arm B: 60% (95% CI: 
49%; 71%), and the LPFSR at 1 and 2 year was 40% and 32% in 
arm A, and 49% and 44%, in arm B. The median LPFSR was 
10.0 m and 10.9 m in arm A and B (p=0.57). The median OS 
was 23.3 m in arm A, and 25.3 m in arm B. The 1 and 2 y 
overall survival was 83% and 46% in arm A, and 81% and 51% 
in arm B (p=0.67). This was similar to the survival in a 
comparable reference group. 
Side effects: Hematological Grade (G) 4 side effects were 
observed in 2 patients in each arm. Dysphagia and dyspnoe 
tended to be higher in arm B. One G4 pneumonitis was 
observed in arm A and 1 G5 in arm B. Mean weight loss was 
2.8% in arm A, and of 1.5% in arm B. The difference was not 
statistically significant. Weight loss of 10-20% was observed in 
7% and 3% of the patients in arm A and B, respectively; but 
no one had a G3 weight loss (≥20%). A late effect esophageal 
stricture/ulceration G3 or more occurred in 3 (5%) of the 
patients in arm A and 4 (7%) in arm B, and one of these in 
arm B was a G5 fistula at the site of the primary tumor.  
Conclusions: The phase II goal was not met in neither of the 
treatment arms. This may be caused by the extensive use of 
PET-CT scan in the study revealing progressions earlier than 
was expected from previous studies, or it could have been 
caused by the omission of concurrent cisplatin. The survival 
of the two arms was however comparable. Since both 
treatment arms were well tolerated with no differences in 
toxicity between the arms, and the 66 Gy arm had a trend to 
better loco-regional control, we have chosen this treatment 
arm (with cisplatin added) as the reference arm in a phase III 
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As a disease of the elderly, cancer poses a unique public 
health problem worldwide. Elderly patients with cancer are 
less likely to receive guideline-based treatment and/or 
participate in clinical trials. At the individual patient level, 
competing risk, perceived efficacy of treatment, and various 
levels of patient/physician preferences all contribute to 
heterogeneity in treatment decision-making. At the 
population level, the economic impact of this variability is 
significant. Costs incurred in the prevention, diagnosis, 
treatment and surveillance of cancer are rising at a rate 
disproportionate to what healthcare systems are able to 
afford. Cost-effectiveness research can be employed to 
determine the suitability of radiotherapy in elderly cancer 
populations through modeling or in the context of clinical 
trials.  Using stereotactic radiotherapy in early stage lung 
cancer as an example, the principals of cost-effectiveness 
research will be explored. Concepts such as cost calculations, 
quality adjusted life expectancy, utilities, and incremental 
cost effectiveness ratios will be introduced. 
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Cancer is increasingly becoming a disease affecting the lives 
of the elderly, especially in more developed countries. Over 
the last 30 years, many patients have experienced the 
mortality lowering benefits of earlier diagnosis and more 
effective treatments. At the same time, the elderly 
population is demographically fast increasing, pronouncing 
even higher prevalence and incidence rates in the near 
future. Among other co-morbidities, second or third cancers 
are not an exception any more. 
Because of large individual variations in physical and mental 
conditions and personal preference of the patient and/or 
family, the treatment decisions seem difficult to fit into 
guidelines. Inclusion in clinical trials is rare. 
Overall, elderly receive (adjuvant) radiotherapy 
and chemotherapy less often, probably because of fear 
for higher rate of complications. In clinical surveys, however, 
elderly don´t suffer from more complications than younger 
patients, except for cardiac complications and postoperative 
death. For most tumours relative survival is lower for the 
elderly, except for patients with colon cancer, prostate 
cancer or indolent NHL. Co-morbidity seems to have an 
independent prognostic effect, except for tumours with a 
very poor prognosis. 
Alternative research strategies need to be sought to improve 
insights on causes of death in this population. Special 
attention is needed for the economical impact of over- versus 
under treatment. Both palliative care and complications 
generate high costs, but reports on costs are rare. Often 
quality of life surveys are lacking late outcome and decision-
making trade offs. Registry based surveys can help insights in 
population-based decision-making, but are lacking co-
morbidity and toxicity data. 
Guidelines are needed to reduce over-treatment but also 
under-treatment, taking into account life-expectancy and co-
morbidities in all our cancer patients. 
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More than 60% of cancer patients is older than 65 years, a 
figure that only will increase the coming decades. As elderly 
patients are underrepresented in clinical trials, treatment 
recommendations for the general population cannot 
straightforwardly be extrapolated to the elderly. 
It is anticipated that intensified treatment regimens are less 
effective in elderly due to physiologic changes occurring with 
aging. Furthermore, higher toxicity rates are expected given 
the high rates of comorbidities and generally poorer 
performance status. Hence, the balance between the 
benefits and risks of a treatment will be different for this 
patient group. In fact, this balance will be different for each 
individual elderly patient: although it is reasonable to spare 
the patient with severe comorbidities or a bad performance 
status an intensive treatment from which he is unlikely to 
benefit and that might even decrease quality of life (QoL), 
the one that is medically fit may benefit from such an 
intensive treatment. Furthermore, given the limited life 
expectancy, QoL and preservation of independence and 
cognition are important to take into account.  
For these reasons, there is an urgent need to design clinical 
trials specific for the elderly, build evidence to guide 
treatment selection in this group and implement it in clinical 
practice. First, reliable tools are needed to distinguish the 
subgroup of fit patients from frail patients, i.e. those 
expected to experience important toxicity. Until now, this 
decision is rather subjective as it is based primarily on the 
physician’s perception whether a patient is deemed fit 
enough to undergo a certain treatment. Geriatric 
assessments have shown to be more predictive for survival, 
dependency and toxicities than age or performance status in 
elderly treated with chemotherapy (Freyer, Ann Oncol 2005; 
Hurria, JCO 2011; Maione JCO 2005), but these have not been 
validated for radiotherapy. The fact that a full geriatric 
assessment is time consuming and is not always reimbursed 
makes it difficult to implement in routine clinical practice. 
Therefore, the EORTC recommends a minimum dataset data 
(MinDS) to be collected, which takes max 5 minutes to 
complete (Pallis, Ann Oncol 2011). It is anticipated that this 
